Zacks Investment Research lowered shares of Chemours Company (The) (NYSE:CC) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday.

According to Zacks, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington. “

Several other analysts also recently commented on the company. Susquehanna Bancshares Inc raised their price objective on Chemours Company (The) from $45.00 to $55.00 and gave the stock a positive rating in a research note on Monday, May 15th. ValuEngine raised Chemours Company (The) from a hold rating to a buy rating in a research note on Friday, June 2nd. BidaskClub downgraded Chemours Company (The) from a buy rating to a hold rating in a research note on Saturday, June 17th. Jefferies Group LLC reaffirmed a buy rating and set a $48.00 price objective on shares of Chemours Company (The) in a research note on Friday, June 16th. Finally, Citigroup Inc. raised their price objective on Chemours Company (The) from $45.00 to $59.00 and gave the stock a buy rating in a research note on Friday, August 4th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Chemours Company (The) currently has an average rating of Buy and an average price target of $51.50.

Shares of Chemours Company (NYSE:CC) opened at 50.36 on Tuesday. The firm has a market capitalization of $9.31 billion, a price-to-earnings ratio of 32.96 and a beta of 3.64. The stock’s 50 day moving average price is $49.94 and its 200-day moving average price is $42.84. Chemours Company has a 12 month low of $14.07 and a 12 month high of $51.59.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The firm’s revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.27 EPS. On average, equities research analysts predict that Chemours Company will post $3.51 EPS for the current fiscal year.

WARNING: “Chemours Company (The) (CC) Cut to “Hold” at Zacks Investment Research” was posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/16/chemours-company-the-cc-cut-to-hold-at-zacks-investment-research.html.

The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Thursday, August 17th were paid a $0.03 dividend. This represents a $0.12 annualized dividend and a dividend yield of 0.24%. The ex-dividend date was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is 8.11%.

In other Chemours Company (The) news, insider E Bryan Snell sold 10,000 shares of Chemours Company (The) stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $46.24, for a total value of $462,400.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Amy Trojanowski sold 2,500 shares of Chemours Company (The) stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $46.03, for a total value of $115,075.00. The disclosure for this sale can be found here. Insiders sold a total of 38,837 shares of company stock worth $1,865,603 in the last three months. Company insiders own 1.14% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CC. BlackRock Inc. raised its stake in shares of Chemours Company (The) by 48,297.2% in the 1st quarter. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company’s stock valued at $737,696,000 after purchasing an additional 19,121,339 shares during the period. FMR LLC raised its stake in shares of Chemours Company (The) by 36.6% in the 1st quarter. FMR LLC now owns 14,925,373 shares of the specialty chemicals company’s stock valued at $574,627,000 after purchasing an additional 3,998,914 shares during the period. Prudential Financial Inc. raised its stake in shares of Chemours Company (The) by 64.1% in the 1st quarter. Prudential Financial Inc. now owns 4,473,227 shares of the specialty chemicals company’s stock valued at $172,219,000 after purchasing an additional 1,747,880 shares during the period. Renaissance Technologies LLC raised its stake in shares of Chemours Company (The) by 135.9% in the 1st quarter. Renaissance Technologies LLC now owns 3,031,400 shares of the specialty chemicals company’s stock valued at $116,709,000 after purchasing an additional 1,746,100 shares during the period. Finally, State Street Corp raised its stake in shares of Chemours Company (The) by 35.1% in the 1st quarter. State Street Corp now owns 5,791,792 shares of the specialty chemicals company’s stock valued at $222,987,000 after purchasing an additional 1,504,657 shares during the period. 72.90% of the stock is currently owned by hedge funds and other institutional investors.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Get a free copy of the Zacks research report on Chemours Company (The) (CC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.